JP6993403B2 - ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 - Google Patents

ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 Download PDF

Info

Publication number
JP6993403B2
JP6993403B2 JP2019506697A JP2019506697A JP6993403B2 JP 6993403 B2 JP6993403 B2 JP 6993403B2 JP 2019506697 A JP2019506697 A JP 2019506697A JP 2019506697 A JP2019506697 A JP 2019506697A JP 6993403 B2 JP6993403 B2 JP 6993403B2
Authority
JP
Japan
Prior art keywords
region
domain
cells
monovalent
mil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019506697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536734A (ja
JP2019536734A5 (OSRAM
Inventor
ヨン ソン キム，
クンオク チョン，
チ ヒ ハ，
イェ チン キム，
ドン キ チェ，
ヘ チ チェ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajou University Industry Academic Cooperation Foundation filed Critical Ajou University Industry Academic Cooperation Foundation
Priority claimed from PCT/KR2017/008676 external-priority patent/WO2018030806A1/ko
Publication of JP2019536734A publication Critical patent/JP2019536734A/ja
Publication of JP2019536734A5 publication Critical patent/JP2019536734A5/ja
Application granted granted Critical
Publication of JP6993403B2 publication Critical patent/JP6993403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019506697A 2016-08-10 2017-08-10 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 Active JP6993403B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20160101823 2016-08-10
KR10-2016-0101823 2016-08-10
KR1020170101594A KR102050463B1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
PCT/KR2017/008676 WO2018030806A1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
KR10-2017-0101594 2017-08-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021033816A Division JP7111855B2 (ja) 2016-08-10 2021-03-03 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2019536734A JP2019536734A (ja) 2019-12-19
JP2019536734A5 JP2019536734A5 (OSRAM) 2020-09-24
JP6993403B2 true JP6993403B2 (ja) 2022-03-03

Family

ID=61524969

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019506697A Active JP6993403B2 (ja) 2016-08-10 2017-08-10 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
JP2021033816A Active JP7111855B2 (ja) 2016-08-10 2021-03-03 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
JP2022116329A Active JP7488854B2 (ja) 2016-08-10 2022-07-21 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021033816A Active JP7111855B2 (ja) 2016-08-10 2021-03-03 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
JP2022116329A Active JP7488854B2 (ja) 2016-08-10 2022-07-21 ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物

Country Status (14)

Country Link
US (4) US10696722B2 (OSRAM)
EP (2) EP4470552A3 (OSRAM)
JP (3) JP6993403B2 (OSRAM)
KR (4) KR102050463B1 (OSRAM)
CN (1) CN110267977A (OSRAM)
AU (2) AU2017310163B2 (OSRAM)
BR (1) BR112019002394B1 (OSRAM)
CA (1) CA3033475A1 (OSRAM)
DK (1) DK3511340T3 (OSRAM)
ES (1) ES3000558T3 (OSRAM)
IL (1) IL264692B2 (OSRAM)
MX (2) MX386014B (OSRAM)
SG (1) SG11201901071TA (OSRAM)
ZA (1) ZA201900772B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3000558T3 (en) 2016-08-10 2025-02-28 Univ Ajou Ind Academic Coop Found Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
AU2018297248A1 (en) 2017-07-03 2020-02-20 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
JP6973828B2 (ja) 2018-02-14 2021-12-01 エルジー・ケム・リミテッド 触媒の充填方法およびこれを用いたブタジエンの製造方法
CN110396133B (zh) * 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
PE20211279A1 (es) 2018-10-23 2021-07-19 Dragonfly Therapeutics Inc Proteinas heterodimericas fusionadas con fc
CN115916233A (zh) * 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
MX2022013112A (es) * 2020-04-22 2023-01-16 Dragonfly Therapeutics Inc Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
US12312418B2 (en) 2020-12-10 2025-05-27 Invenra Inc. Orthogonal mutations for heterodimerization
IL312221A (en) * 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
EP4612165A1 (en) * 2022-11-02 2025-09-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
AU2023378481A1 (en) * 2022-11-10 2025-06-19 Kanglitai Biomedical (Qingdao) Co., Ltd. Site-specific pegylated heteromeric protein or polypeptide, and preparation method therefor and use thereof
WO2024249320A1 (en) * 2023-05-26 2024-12-05 University Of Florida Research Foundation, Incorporated In vivo optimization of biologics
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525423A (ja) 1997-12-08 2001-12-11 レキシジェン ファーマシューティカルズ コーポレイション 標的化免疫治療および一般の免疫刺激に対して有用であるヘテロ二量体融合タンパク質
JP2016506377A (ja) 2012-11-27 2016-03-03 アジュ ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20020055488A1 (en) 2000-09-21 2002-05-09 Wessels Michael R. Prevention and treatment of streptococcal and staphylococcal infection
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
ATE516498T1 (de) 2004-05-20 2011-07-15 Wako Pure Chem Ind Ltd Verfahren zum testen von hyaluronsäure mit hyaluronsäure-bindungsprotein
WO2006130974A1 (en) 2005-06-08 2006-12-14 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
JP5466405B2 (ja) 2006-08-08 2014-04-09 生化学工業株式会社 ヒアルロン酸の分子量の測定方法
WO2008089448A2 (en) 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
DK2247304T3 (en) 2008-04-02 2016-09-26 Macrogenics Inc Her2 / neu-specific antibodies and methods of use thereof
US8034630B2 (en) 2008-04-15 2011-10-11 Wako Pure Chemical Industries, Ltd. Protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
EP2391384A4 (en) 2009-01-29 2012-12-26 Medimmune Llc HUMAN ANTI-IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-TIME AND USE THEREOF FOR TREATMENTS IN ONCOLOGY AND FOR AUTOIMMUNE AND IGNITION
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
CA2813747A1 (en) 2010-10-11 2012-04-19 Chen Wang Processes for purification of proteins
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
TWI807362B (zh) 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
ES2694564T3 (es) 2011-02-10 2018-12-21 Roche Glycart Ag Polipéptidos de interleucina-2 mutantes
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
SG195114A1 (en) 2011-05-24 2013-12-30 Purdue Research Foundation Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
AU2012322999B2 (en) 2011-10-11 2017-08-10 Universitat Zurich Prorektorat Mnw Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy
WO2013110056A1 (en) 2012-01-19 2013-07-25 The Johns Hopkins University Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
US9751919B2 (en) 2012-05-04 2017-09-05 Emergent Biosolutions Canada Inc. Antimicrobial compositions comprising a hyaluronic acid binding peptide and a β-lactam antibiotic
CA2876099A1 (en) 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof
CA2876096A1 (en) 2012-08-02 2014-02-06 Petra Rueger Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
PL3434695T3 (pl) 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
ES2773107T3 (es) 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014150973A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
KR20230164192A (ko) 2014-05-06 2023-12-01 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
KR101721295B1 (ko) 2014-06-11 2017-04-10 주식회사 엘지화학 염화비닐계 수지의 제조방법
US10519234B2 (en) 2014-06-27 2019-12-31 Innate Pharma NKp46 binding proteins
BR112017006591A2 (pt) 2014-11-06 2018-01-16 Hoffmann La Roche polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
US10259859B2 (en) 2015-08-07 2019-04-16 ALX Oncology Inc. Constructs having a SIRP-α domain or variant thereof
EP3359168A4 (en) 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHOD
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
ES3000558T3 (en) 2016-08-10 2025-02-28 Univ Ajou Ind Academic Coop Found Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
WO2018030806A1 (ko) 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
PE20200152A1 (es) 2017-03-27 2020-01-17 Hoffmann La Roche Receptores de union a antigeno mejorados
EP3621714A4 (en) 2017-05-11 2021-01-20 EMD Millipore Corporation METHOD OF MAINTAINING NARROW RESIDENTIAL TIME DISTRIBUTIONS IN CONTINUOUS FLOW SYSTEMS
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
KR102618831B1 (ko) 2017-06-21 2023-12-28 세파론 엘엘씨 양이온 교환 크로마토그래피 세척 완충액
JP2019014449A (ja) 2017-07-10 2019-01-31 トヨタ自動車株式会社 車両用動力伝達装置
MX420258B (es) 2017-09-07 2025-02-10 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y nectina 4.
US11572395B2 (en) 2017-09-21 2023-02-07 Merck Patent Gmbh Fusion protein comprising an FGF-18 moiety
IL273217B2 (en) 2017-09-22 2025-04-01 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
EP3697441B1 (en) 2017-10-20 2023-06-07 F. Hoffmann-La Roche AG Method for generating multispecific antibodies from monospecific antibodies
KR20210042326A (ko) 2018-07-11 2021-04-19 모멘타 파머슈티컬스 인코포레이티드 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
PE20211279A1 (es) 2018-10-23 2021-07-19 Dragonfly Therapeutics Inc Proteinas heterodimericas fusionadas con fc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525423A (ja) 1997-12-08 2001-12-11 レキシジェン ファーマシューティカルズ コーポレイション 標的化免疫治療および一般の免疫刺激に対して有用であるヘテロ二量体融合タンパク質
JP2016506377A (ja) 2012-11-27 2016-03-03 アジュ ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Biological Chemistry，2010年，vol.285, no.25，p.19637-19646
The Journal of Immunology，1998年，vol.160，p.6195-6203

Also Published As

Publication number Publication date
CA3033475A1 (en) 2018-02-15
AU2017310163B2 (en) 2021-09-09
MX2021010809A (es) 2021-10-01
US20230416325A1 (en) 2023-12-28
US11078249B2 (en) 2021-08-03
US20190169252A1 (en) 2019-06-06
EP3511340A4 (en) 2020-03-18
EP3511340B1 (en) 2024-10-02
KR102652247B1 (ko) 2024-03-29
US10696722B2 (en) 2020-06-30
AU2021273642B2 (en) 2025-03-13
EP4470552A3 (en) 2025-03-05
IL264692B2 (en) 2025-12-01
DK3511340T3 (da) 2025-01-02
KR102416411B1 (ko) 2022-07-05
JP2021088601A (ja) 2021-06-10
KR20220098108A (ko) 2022-07-11
JP7488854B2 (ja) 2024-05-22
ES3000558T3 (en) 2025-02-28
US20200362005A1 (en) 2020-11-19
EP4470552A2 (en) 2024-12-04
AU2017310163A1 (en) 2019-03-21
BR112019002394B1 (pt) 2021-12-21
KR102607285B1 (ko) 2023-12-01
MX2019001651A (es) 2019-09-04
BR112019002394A2 (pt) 2019-06-04
JP2019536734A (ja) 2019-12-19
JP7111855B2 (ja) 2022-08-02
EP3511340A1 (en) 2019-07-17
KR20190134564A (ko) 2019-12-04
MX386014B (es) 2025-03-18
JP2022137288A (ja) 2022-09-21
IL264692B1 (en) 2025-08-01
AU2021273642A1 (en) 2021-12-16
US20200362004A1 (en) 2020-11-19
IL264692A (OSRAM) 2019-04-30
US12358964B2 (en) 2025-07-15
KR20230163339A (ko) 2023-11-30
CN110267977A (zh) 2019-09-20
KR20180018419A (ko) 2018-02-21
US11692019B2 (en) 2023-07-04
ZA201900772B (en) 2023-07-26
KR102050463B1 (ko) 2019-11-29
SG11201901071TA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
JP7488854B2 (ja) ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
JP6911105B2 (ja) 抗体重鎖不変部位ヘテロ二量体（ｈｅｔｅｒｏｄｉｍｅｒｉｃ Ｆｃ）に融合したＩＬ−２１（ｈｅｔｅｒｏｄｉｍｅｒｉｃ Ｆｃ−ｆｕｓｅｄ ＩＬ−２１）及びこれを含む薬剤学的組成物
JP2021529557A (ja) 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
JP2022521937A (ja) ＮＫｐ３０に結合する抗体分子およびその使用
JP2002521053A (ja) ヘテロミニ体
KR20240019786A (ko) Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
TWI629284B (zh) 多價抗體片段與其三聚複合物
JP2020536552A (ja) Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用
JP2020536552A5 (OSRAM)
CN103897057B (zh) 多价抗体片段与其三聚复合物
HK40014568A (en) Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same
WO2025160083A1 (en) Targeted low potency il-12 fc fusion proteins and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200811

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200811

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200811

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210823

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210831

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211022

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211209

R150 Certificate of patent or registration of utility model

Ref document number: 6993403

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250